SPT (Antigen Formulation) |
|
Vaxjo ID |
72 |
|
Vaccine Adjuvant Name |
SPT (Antigen Formulation) |
|
Alternative Names |
AF |
|
Adjuvant VO ID |
VO_0001315
|
|
Description |
A vaccine adjuvant vehicle that, when administered with antigen, induces both a cellular and humoral immune response (Vogel and Powell, 1995). |
|
Stage of Development |
Research |
|
Components |
squalane (5%), Tween 80( 0.2%), Pluronic L121( 1.25%), phosphate-buffered saline pH 7.4, and antigen |
|
Structure |
An emulsion of squalane (5%), Tween 80( 0.2%), Pluronic L121( 1.25%), phosphate-buffered saline pH 7.4, and antigen (Vogel and Powell, 1995). |
|
Appearance |
Homogeneous, white milky liquid (Vogel and Powell, 1995). |
|
Storage |
2-8° C under inert gas. Avoid freezing (Vogel and Powell, 1995). |
|
Preparation |
A microemulsion comprised of oil droplets of mean diameter around 150-175 nm. Vialed as a 3X formulation, AF is stable for up to 2 years when stored at 5° C, depending on the concentrations of the excipients used as well as the conditions of microfluidization. A uniform dispersion is achieved when diluting 1:3 with aqueous solution prior to administration (Vogel and Powell, 1995). |
|
Function |
Gives good humoral and CTL responses. A potent cytotoxic T cell response was induced when recombinant soluble antigens were injected with AF leading to the destruction of tumor cells or virally infected cells in vitro and in vivo (Vogel and Powell, 1995). |
|
Safety |
Pathology and toxicology studies completed in two species, including nonhuman primates. It is well tolerated at doses and schedules that exhibit immune stimulating activity. The safety and potency of the three-component microfluidized formulation has been demonstrated in Phase I/II clinical trials (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
